Intra-Cellular Therapies Free Cash Flow 2013-2024 | ITCI

Intra-Cellular Therapies free cash flow for the twelve months ending June 30, 2024 was , a year-over-year.

  • Intra-Cellular Therapies annual free cash flow for 2023 was $-0.124B, a 54.06% decline from 2022.
  • Intra-Cellular Therapies annual free cash flow for 2022 was $-0.271B, a 4.27% increase from 2021.
  • Intra-Cellular Therapies annual free cash flow for 2021 was $-0.26B, a 12.82% increase from 2020.

Intra-Cellular Therapies Free Cash Flow 2013-2024 | ITCI

  • Intra-Cellular Therapies annual free cash flow for 2023 was $-0.124B, a 54.06% decline from 2022.
  • Intra-Cellular Therapies annual free cash flow for 2022 was $-0.271B, a 4.27% increase from 2021.
  • Intra-Cellular Therapies annual free cash flow for 2021 was $-0.26B, a 12.82% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$180.5B
Regeneron Pharmaceuticals (REGN)$126.8B
Vertex Pharmaceuticals (VRTX)$123.3B
Gilead Sciences (GILD)$104.5B
Bristol Myers Squibb (BMY)$99.4B
CSL (CSLLY)$97.5B
GSK (GSK)$86.3B
Alnylam Pharmaceuticals (ALNY)$35.5B
Argenex SE (ARGX)$32.1B
Biogen (BIIB)$29.3B
BioNTech SE (BNTX)$26.8B
Moderna (MRNA)$26.1B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$19.3B
Genmab (GMAB)$17.5B
BioMarin Pharmaceutical (BMRN)$13.6B
Exact Sciences (EXAS)$13.1B
Vaxcyte (PCVX)$13.1B
Insmed (INSM)$12.9B
Incyte (INCY)$12.9B
Bio-Techne Corp (TECH)$12.7B
Sarepta Therapeutics (SRPT)$12.1B
QIAGEN (QGEN)$10.4B
Legend Biotech (LEGN)$9.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.9B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$8.2B
Exelixis (EXEL)$7.7B
Viking Therapeutics (VKTX)$7.6B